Suggestions
Roger Franklin
Partner
Roger Franklin is a Partner at Hadean Ventures, a European life science venture capital firm with offices in Oslo and Stockholm.13 Here are some key details about his background and role:
Professional Experience
Roger Franklin joined Hadean Ventures as a Partner in November 2018.14 He has over a decade of experience in the life science industry, spanning various senior roles in venture capital, investment banking, and strategy consulting.12
Education and Expertise
- PhD in oncology from the University of Cambridge2
- Completed academic training in biochemistry at Oxford University1
- Specializes in oncology, with a particular focus on therapeutics opportunities12
Current Role and Responsibilities
As a Partner at Hadean Ventures, Roger:
- Is based in the Stockholm office at the Karolinska Institute Science Park1
- Focuses on therapeutics opportunities and life science investments across Europe, with a particular emphasis on the Nordic region13
- Brings significant experience in venture and public market transactions1
- Contributes scientific, technical, and operational expertise to the firm1
Board Positions
Roger Franklin holds several board positions, including:
- Board Director of Abliva AB (Sweden)25
- Board Director of TargED Biopharmaceuticals BV (Netherlands)25
- Board Director of Gesynta Pharma AB5
He also serves as a Board Observer for multiple companies, including Pipeline Therapeutics Inc, Step Pharma SAS, Emergence Therapeutics AG, and Cardior Pharmaceuticals GmbH.2
Roger Franklin's extensive experience in life sciences, combined with his strong scientific background and strategic expertise, makes him a valuable asset to Hadean Ventures and its portfolio companies.16
Highlights
Great news today that Novo Nordisk has agreed to acquire Cardior, one of our portfolio companies in the cardiovascular space, for up to Euro 1.025 billion. It’s been a great journey. Congrats to the whole team, been a pleasure working with you. Good job Claudia & Thomas!
Delighted to be joining the board at Complement Therapeutics as part of the €72m Series A financing announced today in which Hadean Ventures invested as part of a syndicate including Forbion, Gimv, BGV, Panakes, CIC and Seroba. Excited to be working with a great team to bring an innovative gene therapy through to P1b clinical PoC in an area of such high unmet need (Geographic Atrophy secondary to dry AMD).
The recent FDA approval of the first intravitreal treatment for GA is a significant milestone for GA patients and the retina community, and further validates the critical role that the complement system plays in the development and progression of GA whilst highlighting the importance of targeting complement as a therapeutic strategy. CTx001 gene therapy, Complement Therapeutic’s lead product, with its novel mechanism of action has the potential to provide superior efficacy compared to competitive drugs and to lower the burden of treatment among patients through a "one and done" approach and thereby transforming the treatment landscape in GA.
